Impact of polycystic ovarian syndrome (pcos) associated with hypertension on some metabolic markers

Abstract

The polycystic ovary syndrome (PCOS) is multifactorial, consisting in hyper androgenic, ovulatory disorders and polycystic appearance of the ovaries. PCOS is a metabolic disorder associated with an increased risk of insulin resistance, hyper insulin blood level, central obesity, high blood pressure, type 2 diabetes, dyslipidemia and cardiovascular disease. The variability of its expression and the difficulty of precise definition hinders the visibility of this disease. Several studies have reported hypertension in obese patients with PCOS. The aim of this work was to study the impact of the combination of hypertension and PCOS on the metabolic disturbances (hepatic, lipid and renal). We recruited 26 hypertensive patients with PCOS in the Tlemcen University Hospital and 30 healthy control women. After obtaining informed consent, the patients benefited from a biochemical assessment of the liver function (transaminases TGO, TGP), the renal function (uric acid, creatinine, urea), and the lipid profile (total cholesterol, LDL, triglycerides). We observed abnormalities of hepatic metabolism, evidenced by elevated levels of transaminases (TGO, TGP), kidney damage by increased creatinine and urea levels, with altered lipid profile in hypertensive women with PCOS compared to control women. In conclusion, PCOS associated with hypertension is associated with numerous metabolic dysfunctions (dyslipidemia, kidney and hepatic impairment). Thus, early dietary and medical management of PCOS is needed to reduce associated metabolic complications.